Kuwait University, Kuwait
Ladislav Novotny was born on October 5, 1955 in Svitavy, Czechoslovakia. He had obtained his Bachelor’s Degree in Pharmaceutical Science from Kharkov Pharmaceutical Institute, Ukraine in 1980; Doctor of Pharmaceutical degree from Charles University in 1981; Doctor of Philosophy degree from Czechoslovak Academy of Sciences in Prague in 1984; Doctor of Science degree from Slovak Academy of Sciences, Bratislava in 1997. He is working as a Professor of Pharmaceutical Chemistry in Kuwait University, since 1998. He is the acting dean of Faculty Pharmacy, since 2003. He is the member of Kuwait Pharmaceutical Association, European Association Cancer Research, American Association Cancer Research, Slovak Pharmacol. Society, Slovak Pharmaceutical Society. He contributed more than 140 articles to reputed Science journals.
Bleomycin, the first-line treatment for many cancers, is present in the clinical administrations as a mixture of related glycopeptides - bleomycin A2 (55-70 %) and bleomycin B2 (25-32 %) together with other minor components. For better understanding of the mechanism of action of different bleomycin fractions, especially the relation to bleomycin resistance, a development of the powerful analytical method with the reliable identification and quantitation of bleomycin in pharmaceutical and biological matrices is highly important. Methods used for the analysis of bleomycins include the approaches based on HPLC-UV with an ion-pair reagent precluding a combination of HPLC and mass spectrometry. Therefore, in this work, an HPLC method based on HILIC (hydrophilic interaction chromatography) principles was proposed for the separation, identification and determination of both major bleomycin fractions when using an on-line combined MS detection (Q-TOFMS). The performance parameters of the HPLC-Q-TOFMS method showed high reliability, selectivity and sensitivity of the method with ng/ml-pg/ml LOD and determination of the accurate molecular weight of the analytes. The applications reported include determination of the bleomycin A2 and B2 in the commercial infusions and identification of bleomycin A2 and B2 in plasma samples. It may be concluded that the proposed HPLC-Q-TOFMS method is a powerful tool for the separation, identification and determination of two major bleomycin fractions with a possibility to determine an accurate molecular weight of these fractions in the samples. The exact characterization as well as simple, sensitive and reliable monitoring in variable multicomponent matrices is made possible by our method.